3.99+0.09+2.31%
10:45:53 AMBTT
Plus500. 81% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Thursday morning 05/30/2024 the Anavex Life Sciences Corp share started trading at the price of $3.93.Compared to the closing price on Wednesday 05/29/2024 on BTT of $3.90, this is a gain of 0.77%.There are 84.64 M shares outstanding in Anavex Life Sciences Corp, which values the company at $345.10 M.
Is Anavex Life Sciences stock a Buy, Sell or Hold?
Anavex Life Sciences stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 1 hold ratings, and 0 sell ratings.What was the 52-week low for Anavex Life Sciences stock?
The low in the last 52 weeks of Anavex Life Sciences stock was 3.25. According to the current price, Anavex Life Sciences is 122.77% away from the 52-week low.What was the 52-week high for Anavex Life Sciences stock?
The high in the last 52 weeks of Anavex Life Sciences stock was 10.44. According to the current price, Anavex Life Sciences is 38.22% away from the 52-week high.What are analysts forecasts for Anavex Life Sciences stock?
The 13 analysts offering price forecasts for Anavex Life Sciences have a median target of 44.54, with a high estimate of 54.00 and a low estimate of 11.00. The median estimate represents a 8.96 difference from the last price of 3.99.Anavex Life Sciences Stock Snapshot
3.99
Bid
100.00
Bid Size
4.00
Ask
260.00
Ask Size
5/30/2024
Date
10:45 AM
Time
5,801.00
Volume
3.90
Prev. Close
3.93
Open
345.10 M
Market Cap
84.64 M
Number of Shares
3.93
Day Low
4.02
Day High
3.99
3.25
52 Week Low
10.44
52 Week High
3.99
-10.92
P/E Ratio
96.85
Free Float in %
-0.52
EPS 2024
Anavex Life Sciences NewsMore News
GlobeNewswire
Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
TipRanks
Buy Rating Justified by Anavex’s Promising Drug Prospects and Solid Financials
TipRanks
Buy Rating on Anavex Life Sciences Amid Promising Alzheimer’s Drug Prospects
Historical Prices for Anavex Life Sciences
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Anavex Life Sciences Analyst Data
Total Analysts: 13
Buy Ratings: 12 Neutral Ratings: 1 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 11.00 Median: 44.54 Highest: 54.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Anavex Life Sciences Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/10/24 | H.C. Wainwright & Co. | Maintained Buy | $40 | gut | ||
| 01/03/24 | H.C. Wainwright & Co. | Maintained Buy | $40 | gut | ||
| 11/28/23 | H.C. Wainwright & Co. | Maintained Buy | $54 | gut | ||
| 08/08/23 | H.C. Wainwright & Co. | Maintained Buy | $54 | gut | ||
| 07/20/23 | H.C. Wainwright & Co. | Maintained Buy | gut | |||
| 06/29/23 | H.C. Wainwright & Co. | Maintained Buy | $54 | gut | ||
| 05/02/23 | H.C. Wainwright & Co. | Maintained Buy | $54 | gut | ||
| 03/31/23 | H.C. Wainwright & Co. | Maintained Buy | $54 | gut | ||
| 02/09/23 | BTIG Research | Maintained Buy | $28 | gut | ||
| 02/09/23 | H.C. Wainwright & Co. | Maintained Buy | $50 | gut | ||
| 02/06/23 | H.C. Wainwright & Co. | Maintained Buy | $50 | gut | ||
| 01/03/23 | H.C. Wainwright & Co. | Maintained Buy | $50 | gut | ||
| 12/06/22 | Cantor Fitzgerald | Downgraded to Hold | $11 | neutral | ||
| 06/23/22 | Berenberg | Maintained Buy | $40 | gut |
Anavex Life Sciences Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3 | 49 | 4 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -0.52 | -0.64 | -0.38 | -0.08 | -0.51 |
| P/E Ratio | -7.81 | -6.34 | -10.68 | -50.75 | -7.96 |
| EBIT | -52 | -63 | -53 | -18 | -66 |
| EBITDA | -75 | 146 | 502 | - | - |
| Net Profit | -44 | -57 | -36 | -7 | -46 |
| Net Profit Adjusted | -70 | 151 | - | - | - |
| Pre-Tax Profit | -43 | -57 | -44 | -9 | -58 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | -0.69 | -0.31 | 14.15 | 15.51 | 13.09 |
| EPS (GAAP) | -0.52 | -0.64 | -0.38 | -0.08 | -0.51 |
| Gross Income | 0 | 241 | 171 | 324 | - |
| Cash Flow from Investing | -7 | -7 | -19 | -36 | - |
| Cash Flow from Operations | -70 | 151 | 133 | 283 | - |
| Cash Flow from Financing | 40 | 0 | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | -70 | 151 | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | - | - | - | - | - |
| Research & Development Exp. | 40 | 47 | 40 | 41 | 52 |
| Capital Expenditure | 0 | 0 | 19 | 36 | - |
| Selling, General & Admin. Exp. | 12 | 16 | 16 | 17 | 18 |
| Shareholder’s Equity | 78 | 354 | 116 | 329 | - |
| Total Assets | 89 | 365 | 213 | 513 | - |
| Previous Quarter | Current Quarter ending 06/30/24 | Next Quarter ending 09/30/24 | Current Year ending 09/30/24 | Next Year ending 09/30/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 2 | 2 | 2 | 2 |
| Average Estimate | - | -0.135 USD | -0.150 USD | -0.520 USD | -0.640 USD |
| Year Ago | - | -0.140 USD | -0.120 USD | -0.600 USD | -0.520 USD |
| Publish Date | - | 5/9/2024 | 8/8/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 2 | 2 | 2 | 2 |
| Average Estimate | - | 0 USD | 0 USD | 0 USD | 0 USD |
| Year Ago | - | - | - | - | 0 USD |
| Publish Date | - | 5/9/2024 | 8/8/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change of sales in % | - | - | - | - | - | - | - |
| Gross profit on sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit on sales change in % | 100.00 | - | - | - | - | - | - |
| Operating income | -16 | -19 | -29 | -31 | -42 | -51 | -56 |
| Operating income change in % | -0.59 | -23.30 | -50.55 | -6.81 | -35.10 | -21.39 | -9.36 |
| Income before tax | -15 | -19 | -29 | -31 | -42 | -51 | -50 |
| Income before tax change in % | -4.87 | -23.25 | -50.86 | -6.81 | -37.72 | -20.75 | 1.43 |
| Income after tax | -13 | -17 | -26 | -26 | -38 | -48 | -48 |
| Income after tax change in % | 8.66 | -29.66 | -50.66 | 0.06 | -44.25 | -26.56 | 0.99 |
Balance Sheet
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 4 | 4 | 5 | 7 | 11 | 10 | 13 |
| Total liabilities change in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity | 24 | 20 | 20 | 27 | 151 | 142 | 142 |
| Equity change in % | 284.49 | -15.51 | -0.98 | 34.24 | 453.73 | -5.52 | -0.45 |
| Balance sheet total | 28 | 24 | 25 | 35 | 162 | 153 | 154 |
| Balance sheet total change in % | 193.08 | -12.44 | 3.91 | 36.37 | 367.88 | -5.51 | 1.10 |
Key Data
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (ear end quote, diluted EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 87.12 | 84.06 | 80.10 | 78.85 | 93.32 | 93.31 | 91.88 |
| Debt ratio in % | 12.88 | 15.94 | 19.90 | 21.15 | 6.68 | 6.69 | 8.12 |
Anavex Life Sciences Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| MISSLING CHRISTOPHER U | 06/28/2023 | 232,000.00 | 1,250,210.00 | 1.60 | Buy | No |
| MISSLING CHRISTOPHER U | 06/27/2023 | 268,000.00 | 1,018,210.00 | 7.98 | Sell | No |
| MISSLING CHRISTOPHER U | 06/27/2023 | 268,000.00 | 1,286,210.00 | 1.60 | Buy | No |
| Skarpelos Athanasios | 05/24/2022 | 50,000.00 | 1,306,458.00 | 9.06 | Sell | No |
| Skarpelos Athanasios | 05/24/2022 | 50,000.00 | 1,356,458.00 | 0.92 | Buy | No |
| Boenisch Sandra | 06/28/2021 | 166,696.00 | 22,963.00 | 26.53 | Sell | No |
| MISSLING CHRISTOPHER U | 06/28/2021 | 51,620.00 | 1,018,210.00 | 26.00 | Sell | No |
| Boenisch Sandra | 06/28/2021 | 35,000.00 | 189,659.00 | 5.92 | Buy | No |
| Boenisch Sandra | 06/28/2021 | 25,000.00 | 47,963.00 | 5.68 | Buy | No |
| Boenisch Sandra | 06/28/2021 | 106,696.00 | 154,659.00 | 3.28 | Buy | No |
| MISSLING CHRISTOPHER U | 06/28/2021 | 51,620.00 | 1,069,830.00 | 1.32 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 145,000.00 | n/a | 11.70 | Sell | No |
| FAVUS ELLIOT | 05/20/2021 | 1,500.00 | 93,500.00 | 5.66 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 50,000.00 | 87,500.00 | 0.92 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 1,500.00 | 95,000.00 | 6.11 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 50,000.00 | 145,000.00 | 2.96 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 37,500.00 | 37,500.00 | 1.20 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 1,500.00 | 89,000.00 | 5.64 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 1,500.00 | 90,500.00 | 5.57 | Buy | No |
| FAVUS ELLIOT | 05/20/2021 | 1,500.00 | 92,000.00 | 4.90 | Buy | No |
| Donhauser Peter D.O. | 05/16/2021 | 1,000.00 | 2,165.00 | 10.93 | Buy | No |
| FAVUS ELLIOT | 02/23/2021 | 145,500.00 | n/a | 12.66 | Sell | No |
| FAVUS ELLIOT | 02/23/2021 | 45,500.00 | 45,000.00 | 2.58 | Buy | No |
| FAVUS ELLIOT | 02/23/2021 | 100,000.00 | 145,000.00 | 3.28 | Buy | No |
| Donhauser Peter D.O. | 02/18/2021 | 165.00 | 1,165.00 | 12.97 | Buy | No |
Anavex Life Sciences Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2022 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2021 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2020 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2019 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2018 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2017 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2016 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2015 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2014 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2013 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2012 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2011 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2010 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
| 2009 | Anavex Life Sciences Corp | 0.00 | 0.00 | USD |
*Yield of the Respective Date
Anavex Life Sciences Corp Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.150 USD | Q3 2024 Earnings Release | 08/08/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 11/25/2024 |
| Earnings Report | - | Q1 2025 Earnings Release | 02/06/2025 |
| Earnings Report | - | Q2 2025 Earnings Release | 05/08/2025 |
Anavex Life Sciences Corp Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | -0.130 USD | Q2 2024 Earnings Release | 05/09/2024 |
Anavex Life Sciences Profile
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Moody’s Daily Credit Risk Score
Risk
- Low
- Medium
- High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Anavex Life Sciences Shareholder
| Owner | in % |
|---|---|
| Freefloat | 96.85 |
| State Street Corp. | 8.89 |
| SPDR S&P Biotech ETF | 6.44 |
| The Vanguard Group, Inc. | 5.31 |
| Vanguard Group, Inc. (Subfiler) | 5.13 |
| SSgA Funds Management, Inc. | 4.44 |
| BlackRock Fund Advisors | 4.34 |
| Vanguard Total Stock Market ETF | 2.87 |
| BlackRock Institutional Trust Co. NA | 2.84 |
| Geode Capital Management LLC | 2.09 |
| iShares Russell 2000 ETF | 2.05 |
| Athanasios Skarpelos | 1.59 |
| Christopher U. Missling, PhD, MBA | 1.52 |
| Vanguard Extended Market Index Fund | 1.49 |
| NWAM LLC | 1.02 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
